Breaking News
January 17, 2018 - Top nutrients needed to boost mood and energy levels on Blue Monday
January 17, 2018 - Scientists develop unique technique to map elasticity of cell components
January 17, 2018 - Obesity surgery reduces the risk of death by half finds new study
January 17, 2018 - Raw Meat Not the Safest Choice for Your Dog or for You
January 17, 2018 - Men who lack HSD17B4 gene may be more susceptible to treatment-resistant prostate cancer
January 17, 2018 - High-Dose Aspirin Preferred for Kawasaki’s
January 17, 2018 - Study suggests risk management approach to combat EMS fatigue
January 17, 2018 - A new therapy against obesity
January 17, 2018 - Doctors warn against holding your nose and closing your mouth to contain a sneeze
January 17, 2018 - Measles outbreak alarms public health officials
January 17, 2018 - FDA Slaps Class Warning on Gadolinium Contrast Agents
January 17, 2018 - Distinct human mutations can alter the effect of medicine
January 17, 2018 - ASIT biotech’s new article presents clinical results of gp
January 17, 2018 - Alternative tobacco use by adolescents associated with greater odds of future cigarette smoking
January 17, 2018 - A High-Salt Diet Produces Dementia In Mice
January 17, 2018 - Scientists provide insights into crucial interaction for DNA repair
January 17, 2018 - Sanofi and Regeneron Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
January 17, 2018 - Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
January 17, 2018 - Researchers see gene influencing performance of sleep-deprived people
January 17, 2018 - Fast food triggers the immune system making it hyperactive
January 17, 2018 - Scientists find increased risk of HIV outbreaks in Ukraine due to war-related migration
January 17, 2018 - New universal flu vaccine moves to clinical trial phase and could be a reality soon
January 17, 2018 - Cocaine de-addiction breakthrough shows promise
January 17, 2018 - FDA Accepts New Drug Application for Seysara (sarecycline) for the Treatment of Moderate to Severe Acne
January 17, 2018 - Robotic Telestenting; BP Cuff Smartwatch; Medicare Bundled Care
January 17, 2018 - New cellular approach found to control progression of chronic kidney disease
January 17, 2018 - Lamprey genes provide clues to repair spinal cord damage, finds study
January 17, 2018 - Tissue-based soft robot could lead to advances in bio-inspired robotics
January 17, 2018 - Mostly the healthy and wealthy Americans use mobile phone apps to track sleep habits
January 17, 2018 - FDA Alert: Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter
January 16, 2018 - NeuroBreak: Rough Days for Neuroscience Research; Another Migraine Drug Advances
January 16, 2018 - The ‘greatest pandemic in history’ was 100 years ago – but many of us still get the basic facts wrong
January 16, 2018 - Serena Williams Shares Childbirth Ordeal
January 16, 2018 - The Artificial Brain as Doctor
January 16, 2018 - Type 2 diabetes has hepatic origins
January 16, 2018 - Expert discusses how to identify, support individuals with drug or alcohol addiction in workplace
January 16, 2018 - Starting menstruation early increases risk of cardiovascular disease and stroke in later life
January 16, 2018 - CapsoVision receives CE Mark approval for use of CapsoCam Plus System in pediatric patients
January 16, 2018 - Researchers develop new dynamic statistical model to follow gene expressions over time
January 16, 2018 - Alzheimer’s ‘looks like me, it looks like you’
January 16, 2018 - By the Numbers: Physicians’ Economic Impact
January 16, 2018 - Sound Health | NIH News in Health
January 16, 2018 - Modifying baby formula doesn’t prevent type 1 diabetes in children
January 16, 2018 - Energy drinks dangerous for kids
January 16, 2018 - When you need a breast screening, should you get a 3-D mammogram?
January 16, 2018 - Johns Hopkins gets approval to perform HIV positive to HIV positive living donor kidney transplants
January 16, 2018 - The Salk Institute and Indivumed collaborate for cutting-edge cancer research
January 16, 2018 - Study reveals negative long-term effects of heavy cannabis use on brain function and behavior
January 16, 2018 - Many gym-goers injure themselves by pushing harder to be better than friends
January 16, 2018 - Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
January 16, 2018 - Federal Junk Food Tax Feasible, Study Says
January 16, 2018 - Do girls have stronger teeth than boys?
January 16, 2018 - New high-sensitivity blood tests could aid faster diagnosis and treatment for heart attack
January 16, 2018 - How fatal mitochondrial diseases may strike offspring of families with no history of the conditions
January 16, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
January 16, 2018 - Morning Break: Food Pharmacies; Obamacare Sign-ups Dip; Top Pot Studies
January 16, 2018 - Blood pressure declines 14 to 18 years before death
January 16, 2018 - ViLim Ball technology helps reduce uncontrollable shaking hands
January 16, 2018 - Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies
January 16, 2018 - In Wisconsin, hopes rise for production of a lifesaving radioactive isotope
January 16, 2018 - Researchers develop software to better predict risk of leakage around aortic stents
January 16, 2018 - Bile acids could directly burn away lipids in the fat depots
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Severe peer victimization in childhood may contribute to mental health issues in adolescence
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
Genius Delayed: HIV Vaccines Still in the Works

Genius Delayed: HIV Vaccines Still in the Works

image_pdfDownload PDFimage_print

In February, mixed results were reported from a small trial with a candidate HIV vaccine, but researchers nevertheless said they were encouraged that they were on the right track. Click here to read MedPage Today’s report on that presentation. In this follow-up article, we examine what has happened since with the efforts to bring an HIV vaccine into clinical use.

In retrospect, you have to forgive Margaret Heckler’s optimism.

In 1984, Heckler — then secretary of Health And Human Services — told reporters that the cause of AIDS had been pinned down and that a blood test for the virus, then dubbed HTLV-III, had been developed.

A vaccine, she expected, would follow in the next couple of years. “Yet another terrible disease is about to yield to patience, persistence, and outright genius,” Heckler said.

What Heckler could not know, in those early years, is exactly how much patience, persistence, and genius would be needed. There is still no vaccine for HIV 33 years later and counting — but 2017 was a year of renewed optimism and clinical endeavor.

The search for a vaccine is now more nuanced. Two large randomized trials are investigating drugs that would bar the door to HIV infection in the first place — pretty much the layman’s understanding of what a vaccine does. Those trials are what HIV vaccine research has been about from the beginning — big studies with a potential for a big pay-off.

But other studies are looking at “therapeutic” vaccines, which would boost the immune systems of people already infected so they could control the virus without the need for daily antiviral medications.

On the latter front, there is now some optimism. In February, Beatriz Mothe, MD, PhD, of the Spanish AIS research institute IrsiCaixa in Barcelona, reported early details of a small study that gave, for the first time, a positive signal for a therapeutic vaccine strategy.

At the annual Conference on Retroviruses and Opportunistic Infections (CROI), Mothe reported that five people in a 15-patient trial had been able to keep the virus under control after stopping anti-HIV medications.

“They go up, they go down” but their HIV viral load remains relatively low, she told MedPage Today at the time. That’s a contrast to what usually happens when HIV patients stop taking their drugs — an almost immediate and precipitous increase in HIV.

The study has just finished, Mothe told MedPage Today recently, and the investigators are in the midst of finalizing and analyzing the data.

The viral control she reported at CROI was sustained in four patients throughout the 8-month trial and she and colleagues are now studying the virology and immunology of the participants to try to generate a hypothesis to explain the effect.

“As you can imagine, with such a small non-controlled trial, it is challenging to decipher the exact mechanisms that may explain the observed effect,” she said in an email. The researchers hope to publish their data in the next few months.

Outside experts said they were excited by the report, but cautioned it was early days. Mothe said she and colleagues are starting new trials with novel vaccine candidates that they hope will have even more of an effect.

As Mothe pointed out, the lack of a control group is a challenge for such studies. Exactly how much of a challenge was made clear later in the year.

In December, investigators from the National Institute of Allergy and Infectious Diseases (NIAID) and colleagues reported the null outcome of a placebo-controlled trial of another therapeutic vaccine strategy.

Placebo-controlled trials have been rare on the therapeutic vaccine front, largely because — by definition — participants are already infected and there is a risk associated with stopping anti-HIV drugs.

But in the NIAID trial, the researchers found it was possible to use a placebo control group safely. And they re-learned the important lesson that a control group yields valuable information about efficacy.

Many participants treated with the vaccine candidate stopped their anti-HIV medicines and did quite well for some time but so did those given a placebo. Indeed, had the trial simply compared treated patients with historical controls, the researchers might have concluded — wrongly — that they had something that worked.

The investigators pointed out that the effect they saw was very similar to what Mothe and colleagues observed.

On the preventive front, of course, placebo control is the rule. But here again, it has been a challenge to demonstrate efficacy: Only one study has shown any benefit from a vaccine candidate.

In 2009, investigators showed that a vaccine strategy tested in Thailand yielded some protection against infection — an estimated 31%. But the estimate had a wide confidence interval, from 1.1% to 52.1%, and in any case it wasn’t a strong enough result to justify using the strategy clinically.

But the approach used in that trial, dubbed RV-144, is being tested again — after some tweaks. Researchers first pored over the RV-144 data looking for clues to even that small efficacy. Then, using those clues, they re-engineered the vaccines and re-designed the way they would be used.

Late last year, a new trial, dubbed HVTN 702, kicked off in South Africa, with the goal of enrolling 5,400 people and delivering at least 50% vaccine efficacy. A spokesperson for the trial said more than 2,200 participants have already enrolled.

One reason the new trial took a long time to get under way is that the vaccines — there are actually two substances, used in a prime-boost fashion — had to be modified so they were aimed at the HIV clade that circulates in South Africa.

If it proves to be effective when results are available in 2020, variants would be needed for each HIV clade around the world.

That’s why there is some excitement about the second trial now under way — the so-called Imbokodo trial, a phase IIb proof-of-concept study, has just started enrolling 2,600 HIV-negative women in sub-Saharan Africa. The study will look at safety and efficacy.

The vaccine candidate under study is based on what are called “mosaic” immunogens — vaccine components designed to induce immune responses against a wide variety of HIV clades. In other words, if it proves to work, there would be no need to tweak the vaccine for different regions.

Results from Imbokodo (also known as HPTN 705) should be available in about 4 years.


Tagged with:

About author

Related Articles